<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Epidemiology and causes of secondary amenorrhea</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Epidemiology and causes of secondary amenorrhea</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Epidemiology and causes of secondary amenorrhea</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Corrine K Welt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert L Barbieri, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William F Crowley, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H689399507"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Amenorrhea (absence of menses) can be a transient, intermittent, or permanent condition resulting from dysfunction of the hypothalamus, pituitary, ovaries, uterus, or vagina  (<a class="graphic graphic_table graphicRef59801" href="/d/graphic/59801.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef73995" href="/d/graphic/73995.html" rel="external">table 2</a>). It is often classified as either primary (absence of menarche by age 15 years) or secondary (absence of menses for more than three months in females who previously had regular menstrual cycles or six months in females who had irregular menses). Missing a single menstrual period may not be important to assess, but amenorrhea lasting three months or more and oligomenorrhea (fewer than nine menstrual cycles per year or cycle length greater than 35 days) require investigation. An intermenstrual interval greater than 45 days is considered abnormal in adolescent females who are ≥2 years postmenarche [<a href="#rid1">1</a>]. The etiologic and diagnostic considerations for oligomenorrhea are the same as for secondary amenorrhea.</p><p>The epidemiology and causes of secondary amenorrhea are reviewed here. An overview of the normal menstrual cycle, evaluation and management of secondary amenorrhea, and the causes, evaluation, and management of primary amenorrhea are discussed separately. (See  <a class="medical medical_review" href="/d/html/7418.html" rel="external">"Normal menstrual cycle"</a> and  <a class="medical medical_review" href="/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/104218.html" rel="external">"Causes of primary amenorrhea"</a> and  <a class="medical medical_review" href="/d/html/7403.html" rel="external">"Evaluation and management of primary amenorrhea"</a>.)</p><p class="headingAnchor" id="H689400970"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The most common causes of secondary amenorrhea, based upon a series of 262 patients with amenorrhea of adult onset, include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothalamus</strong> – 35 percent (almost all functional hypothalamic amenorrhea) (see <a class="local">'Functional hypothalamic amenorrhea'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pituitary</strong> – 17 percent (13 percent hyperprolactinemia, 1.5 percent "empty sella," 1.5 percent Sheehan syndrome, 1 percent Cushing syndrome) (see <a class="local">'Pituitary disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovary</strong> – 40 percent (30 percent polycystic ovary syndrome [PCOS], 10 percent primary ovarian insufficiency [POI, also known as premature ovarian failure]) (see <a class="local">'Polycystic ovary syndrome'</a> below and <a class="local">'Primary ovarian insufficiency (premature ovarian failure)'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uterus</strong> – 7 percent (all due to intrauterine adhesions) (see <a class="local">'Uterine disorders'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – 1 percent (congenital adrenal hyperplasia, ovarian and adrenal tumors, hypothyroidism) (see <a class="local">'Other hyperandrogenic disorders'</a> below and <a class="local">'Thyroid disease'</a> below)</p><p></p><p>Similar results have been seen in other studies [<a href="#rid3">3,4</a>]. The breakdown may be slightly different in adolescents with irregular menses, 50 percent of whom have hyperandrogenism likely attributed to PCOS [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H689399560"><span class="h1">CAUSES</span></p><p class="headingAnchor" id="H689399567"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Pregnancy is the most common cause of secondary amenorrhea. It may occur even in females who claim that they have not been sexually active or are positive that intercourse occurred at a "safe" time. It is also important to note that apparent menstrual bleeding does not exclude pregnancy, since a substantial number of pregnancies are associated with some early first trimester bleeding. Thus, a pregnancy test (measurement of serum or urinary human chorionic gonadotropin [hCG]) is recommended as a first step in evaluating any female with amenorrhea. (See  <a class="medical medical_review" href="/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea", section on 'Initial evaluation'</a>.)</p><p class="headingAnchor" id="H689399611"><span class="h2">Hypothalamic dysfunction</span></p><p class="bulletIndent1"><span class="glyph">●</span>One of the most common types of secondary amenorrhea is functional hypothalamic amenorrhea, which, by definition, excludes pathologic disease. (See <a class="local">'Functional hypothalamic amenorrhea'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although isolated gonadotropin-releasing hormone (GnRH) deficiency most commonly presents as primary amenorrhea, it extremely rarely presents as secondary amenorrhea. There have been some reports of a single menstrual bleed in selected cases (eg, with GnRH receptor mutations, which may not cause complete receptor dysfunction [<a href="#rid6">6</a>]). (See  <a class="medical medical_review" href="/d/html/7465.html" rel="external">"Isolated gonadotropin-releasing hormone deficiency (idiopathic hypogonadotropic hypogonadism)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Benign and malignant tumors in the hypothalamus, such as craniopharyngiomas, radiation of sellar tumors, and infiltrative diseases of the hypothalamus, can cause secondary amenorrhea. (See <a class="local">'Hypothalamic tumors and infiltrative lesions'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic illness may be associated with menstrual cycle disorders when it is severe enough to result in a decrease in hypothalamic GnRH secretion and/or when it is associated with nutritional deficiencies. (See <a class="local">'Systemic illness'</a> below.)</p><p></p><p class="headingAnchor" id="H689399617"><span class="h3">Functional hypothalamic amenorrhea</span><span class="headingEndMark"> — </span>Functional hypothalamic amenorrhea, or functional hypothalamic GnRH deficiency, is a disorder that, by definition, excludes pathologic disease. It is characterized by a presumed decrease in hypothalamic GnRH secretion [<a href="#rid7">7,8</a>].</p><p>The abnormal GnRH secretion characteristic of functional hypothalamic amenorrhea leads to decreased pulses of gonadotropins, absence of normal follicular development, absent midcycle surges in luteinizing hormone (LH) secretion, anovulation, and low serum estradiol concentrations [<a href="#rid9">9</a>]. Variable neuroendocrine patterns of LH secretion can be seen [<a href="#rid10">10</a>]. Serum concentrations of follicle-stimulating hormone (FSH) are low or normal and often exceed those of LH, similar to the pattern in prepubertal females.</p><p>One of the main clinical concerns in females with functional hypothalamic amenorrhea is bone loss due to hypoestrogenemia. (See  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/110816.html" rel="external">"Functional hypothalamic amenorrhea: Evaluation and management"</a> and  <a class="medical medical_review" href="/d/html/86685.html" rel="external">"Anorexia nervosa: Endocrine complications and their management", section on 'Bone'</a>.)</p><p class="headingAnchor" id="H689399699"><span class="h4">Risk factors</span><span class="headingEndMark"> — </span>Multiple factors may contribute to the pathogenesis of functional hypothalamic amenorrhea, including eating disorders (such as anorexia nervosa), excessive exercise, and stress. However, in a few females with functional hypothalamic amenorrhea, no obvious precipitating factor is evident. The term hypothalamic amenorrhea is often used interchangeably with functional hypothalamic amenorrhea (FHA). FHA is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7393.html" rel="external">"Functional hypothalamic amenorrhea: Pathophysiology and clinical manifestations"</a> and  <a class="medical medical_review" href="/d/html/110816.html" rel="external">"Functional hypothalamic amenorrhea: Evaluation and management"</a>.) </p><p class="headingAnchor" id="H689400126"><span class="h3">Hypothalamic tumors and infiltrative lesions</span><span class="headingEndMark"> — </span>Hypothalamic tumors, (eg, craniopharyngiomas, lymphomas) and infiltrative diseases (eg, Langerhans cell histiocytosis, sarcoidosis) may result in decreased GnRH secretion, low or normal serum gonadotropin concentrations, and amenorrhea. However, these lesions are uncommon compared with functional hypothalamic amenorrhea. Most females with infiltrative disease of the hypothalamus who have amenorrhea will have one or more neurologic symptoms, such as severe headache, change in personality, or marked mood changes. (See  <a class="medical medical_review" href="/d/html/4834.html" rel="external">"Neurologic sarcoidosis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/8385.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis", section on 'Endocrinopathies'</a>.)</p><p class="headingAnchor" id="H689400154"><span class="h3">Systemic illness</span><span class="headingEndMark"> — </span>Systemic illness may be associated with menstrual cycle disorders when it is severe enough to result in a decrease in hypothalamic GnRH secretion and/or when it is associated with nutritional deficiencies. Examples include type 1 diabetes mellitus and celiac disease, which may also present with autoimmune ovarian insufficiency. (See <a class="local">'Primary ovarian insufficiency (premature ovarian failure)'</a> below and  <a class="medical medical_review" href="/d/html/166.html" rel="external">"Causes of primary adrenal insufficiency (Addison disease)", section on 'Autoimmune adrenalitis'</a>.)</p><p class="headingAnchor" id="H689400172"><span class="h4">Type 1 diabetes mellitus</span><span class="headingEndMark"> — </span>Adolescent females with type 1 diabetes mellitus have an increased prevalence of oligomenorrhea and amenorrhea. In one study, 39 of 56 (70 percent) adolescents with type 1 diabetes mellitus had amenorrhea or oligomenorrhea compared with 12 of 56 (22 percent) controls. The adolescents with type 1 diabetes mellitus and glycated hemoglobin (A1C) concentrations &gt;7.6 percent were more likely to have menstrual abnormalities [<a href="#rid11">11</a>]. Even in well-controlled adults with type 1 diabetes mellitus, the prevalence of amenorrhea is 20 percent [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Miscellaneous'</a>.)</p><p>Type 2 diabetes in adolescent females may be associated with polycystic ovary syndrome (PCOS) and menstrual cycle disorders. (See  <a class="medical medical_review" href="/d/html/5820.html" rel="external">"Epidemiology, presentation, and diagnosis of type 2 diabetes mellitus in children and adolescents"</a>.)</p><p class="headingAnchor" id="H689400204"><span class="h4">Celiac disease</span><span class="headingEndMark"> — </span>It is estimated that approximately 40 percent of females with untreated celiac disease have menstrual cycle disorders [<a href="#rid13">13</a>]. Other reproductive problems in these females include delayed menarche, infertility, miscarriage, and pregnancy complications. (See  <a class="medical medical_review" href="/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Menstrual and reproductive issues'</a>.)</p><p class="headingAnchor" id="H689400258"><span class="h2">Pituitary disease</span><span class="headingEndMark"> — </span>Among pituitary disorders that cause secondary amenorrhea, lactotroph adenomas (prolactin-secreting pituitary adenomas, prolactinomas) are the most common. They are responsible for 13 percent of cases of secondary amenorrhea and 90 percent of the cases due to pituitary disease [<a href="#rid2">2</a>]. Other types of pituitary adenomas and other sellar masses, and other types of pituitary disease, account for the majority of the remaining cases of pituitary origin. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H689400290"><span class="h3">Hyperprolactinemia</span><span class="headingEndMark"> — </span>Hyperprolactinemia has a similar presentation to functional hypothalamic amenorrhea, except for the additional finding of galactorrhea in some females. As a result, serum prolactin should be measured in every female with amenorrhea. The normal range should be consulted for the prolactin assay used, as the upper limit of normal for females of reproductive age can range from 20 to 27 ng/mL (20 to 27 mcg/L). Stress, sleep, and intercourse can also raise serum prolactin. Thus, we recommend that serum prolactin be measured at least twice before sellar imaging is ordered, particularly in females with borderline high values (&lt;50 ng/mL [&lt;50 mcg/L]). The causes, clinical manifestations, and evaluation of hyperprolactinemia are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/6626.html" rel="external">"Causes of hyperprolactinemia"</a> and  <a class="medical medical_review" href="/d/html/6638.html" rel="external">"Clinical manifestations and evaluation of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H689400334"><span class="h3">Other sellar masses</span><span class="headingEndMark"> — </span>Any other sellar mass (such as other kinds of pituitary adenomas, craniopharyngiomas, meningiomas, cysts, etc) can also cause deficient gonadotropin secretion and therefore amenorrhea, with or without hyperprolactinemia. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p class="headingAnchor" id="H689400352"><span class="h3">Other diseases of the pituitary</span><span class="headingEndMark"> — </span>Sheehan syndrome, radiation, infarction, and infiltrative lesions of the pituitary gland, such as hemochromatosis and lymphocytic hypophysitis, are all uncommon causes of gonadotropin deficiency. (See  <a class="medical medical_review" href="/d/html/6636.html" rel="external">"Causes of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H689400382"><span class="h2">Thyroid disease</span><span class="headingEndMark"> — </span>Menstrual cycle disorders are common in females with thyroid disease. This was illustrated in a report of over 1000 females with a thyroid disorder [<a href="#rid14">14</a>]. Menstrual disturbances were common in females with hypothyroidism (35 and 10 percent for severe and mild-moderate hypothyroidism, respectively) [<a href="#rid14">14</a>] (see  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Reproductive abnormalities'</a>). In females with severe hyperthyroidism, amenorrhea and hypomenorrhea occurred in 2.5 and 3.7 percent, respectively. Rates were lower in those with mild to moderate hyperthyroidism (0.2 and 0.9 percent, respectively).</p><p>Although heavy bleeding is the typical bleeding pattern seen with hypothyroidism, secondary amenorrhea can also occur [<a href="#rid15">15</a>]. It is important to recognize hypothyroidism as a potential cause of a reversibly enlarged pituitary gland (due to thyrotroph hyperplasia, lactotroph hyperplasia, or both) and hyperprolactinemia and not to confuse this entity with a lactotroph adenoma [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/7846.html" rel="external">"Clinical manifestations of hypothyroidism", section on 'Reproductive abnormalities'</a>.)</p><p class="headingAnchor" id="H689400484"><span class="h2">Polycystic ovary syndrome</span><span class="headingEndMark"> — </span>PCOS, the most common reproductive disorder in females, accounts for approximately 20 percent of cases of amenorrhea but may account for approximately 50 percent of cases of oligomenorrhea [<a href="#rid5">5</a>] (see <a class="local">'Epidemiology'</a> above). Of note, PCOS is not simply an ovarian disorder; its pathogenesis is complex. (See  <a class="medical medical_review" href="/d/html/7430.html" rel="external">"Epidemiology, phenotype, and genetics of the polycystic ovary syndrome in adults", section on 'Pathogenesis'</a>.)</p><p>The principal features of PCOS include androgen excess, ovulatory dysfunction, and/or polycystic ovaries. In addition, many females with PCOS are overweight or obese and have insulin resistance. Females with PCOS may present with amenorrhea, but they more commonly have irregular menses (oligomenorrhea). PCOS is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a> and  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H983971564"><span class="h3">Other hyperandrogenic disorders</span><span class="headingEndMark"> — </span>Disorders other than PCOS that are associated with hyperandrogenism (eg, classic or nonclassic 21-hydroxylase deficiency and androgen-secreting tumors) may cause menstrual cycle disorders by causing anovulation or endometrial atrophy [<a href="#rid18">18,19</a>]. Exogenous androgens (eg, androgen abuse) can have the same effect. (See  <a class="medical medical_review" href="/d/html/7475.html" rel="external">"Use of androgens and other hormones by athletes", section on 'Reproductive (women)'</a> and  <a class="medical medical_review" href="/d/html/7439.html" rel="external">"Pathophysiology and causes of hirsutism", section on 'Causes'</a>.)</p><p class="headingAnchor" id="H983971644"><span class="h2">Ovarian disorders</span></p><p class="headingAnchor" id="H689400554"><span class="h3">Primary ovarian insufficiency (premature ovarian failure)</span><span class="headingEndMark"> — </span>The depletion of oocytes before age 40 years is called primary ovarian insufficiency (POI, or premature ovarian failure). Most females experience intermittent follicular development, estradiol production, LH surges, ovulation, and menstrual bleeding between months of hypoestrogenemia. When POI is complete, lack of ovarian function leads to estrogen deficiency, endometrial atrophy, and cessation of menstruation. Despite the intermittent ovarian function, conception is rare once a diagnosis of POI has been made. (See  <a class="medical medical_review" href="/d/html/7443.html" rel="external">"Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p>Loss of the negative feedback effect of estradiol and inhibin on the hypothalamus and pituitary results in high serum FSH concentrations, which distinguishes ovarian insufficiency from hypothalamic amenorrhea (low or normal FSH). (See  <a class="medical medical_review" href="/d/html/7395.html" rel="external">"Clinical manifestations and diagnosis of menopause", section on 'Menstrual cycle and endocrine changes'</a>.)</p><p>POI may be due to complete or partial loss of an X chromosome (Turner syndrome), the fragile X premutation, autoimmune ovarian destruction, or, most commonly, unknown and rare causes. Radiation therapy or chemotherapy with alkylating agents such as <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> may also result in POI. POI is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7435.html" rel="external">"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7443.html" rel="external">"Clinical manifestations and diagnosis of primary ovarian insufficiency (premature ovarian failure)"</a> and  <a class="medical medical_review" href="/d/html/7426.html" rel="external">"Management of primary ovarian insufficiency (premature ovarian failure)"</a>.)</p><p class="headingAnchor" id="H983971843"><span class="h3">Ovarian tumors</span><span class="headingEndMark"> — </span>Rare cases of ovarian tumors secreting inhibin may present with secondary amenorrhea. In one patient, an ovarian fibrothecoma producing inhibin B resulted in suppressed FSH and estradiol concentrations, amenorrhea, and hot flashes [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/16833.html" rel="external">"Sex cord-stromal tumors of the ovary: Epidemiology, clinical features, and diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H689400665"><span class="h2">Uterine disorders</span><span class="headingEndMark"> — </span>Intrauterine adhesions (Asherman syndrome) are the only uterine cause of secondary amenorrhea. This syndrome results from acquired scarring of the endometrial lining, usually secondary to postpartum hemorrhage or endometrial infection followed by instrumentation such as a dilatation and curettage. This abnormality prevents the normal build-up and shedding of endometrial cells, leading to very light or absent menses. The etiology of and evaluation for intrauterine adhesions is reviewed separately. (See  <a class="medical medical_review" href="/d/html/3285.html" rel="external">"Intrauterine adhesions: Clinical manifestation and diagnosis", section on 'Etiology and risk factors'</a> and  <a class="medical medical_review" href="/d/html/7402.html" rel="external">"Evaluation and management of secondary amenorrhea", section on 'Normal laboratory results and history of uterine instrumentation'</a>.)</p><p class="headingAnchor" id="H1812752123"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114189.html" rel="external">"Society guideline links: Amenorrhea"</a>.)</p><p class="headingAnchor" id="H2560327"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy </strong>–<strong> </strong>Pregnancy is the most common cause of secondary amenorrhea. (See <a class="local">'Pregnancy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>–<strong> </strong>Aside from pregnancy, the estimated frequencies of the different causes of secondary amenorrhea include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hypothalamic</strong> – 35 percent (almost all functional hypothalamic amenorrhea) (see <a class="local">'Functional hypothalamic amenorrhea'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pituitary</strong> – 17 percent (13 percent hyperprolactinemia, 1.5 percent "empty sella," 1.5 percent Sheehan syndrome, 1 percent Cushing syndrome) (see <a class="local">'Pituitary disease'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ovary</strong> – 40 percent (30 percent polycystic ovary syndrome [PCOS], 10 percent primary ovarian insufficiency [POI, also known as premature ovarian failure]) (see <a class="local">'Polycystic ovary syndrome'</a> above and <a class="local">'Primary ovarian insufficiency (premature ovarian failure)'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uterus</strong> – 7 percent (all due to intrauterine adhesions) (see <a class="local">'Uterine disorders'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other</strong> – 1 percent (classic or nonclassic 21-hydroxylase deficiency, hypothyroidism, ovarian and adrenal tumors)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothalamic and pituitary disorders </strong>–<strong> </strong>A number of hypothalamic or pituitary disorders can result in secondary amenorrhea, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Functional hypothalamic amenorrhea</strong> – Functional hypothalamic amenorrhea or functional hypothalamic gonadotropin-releasing hormone (GnRH) deficiency, which by definition excludes pathologic disease. One of the main clinical concerns in females with functional hypothalamic amenorrhea is bone loss due to hypoestrogenemia. Risk factors for functional hypothalamic amenorrhea include weight loss, exercise associated with low weight (running, ballet dancing), nutritional deficiencies, and stress. (See <a class="local">'Functional hypothalamic amenorrhea'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic illness </strong>–<strong> </strong>Systemic illness when it is severe enough to result in a decrease in hypothalamic GnRH secretion and/or when it is associated with nutritional deficiencies. Examples include type 1 diabetes mellitus and celiac disease. (See <a class="local">'Systemic illness'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hyperprolactinemia </strong>–<strong> </strong>Hyperprolactinemia, most commonly due to lactotroph adenomas (prolactinomas). (See <a class="local">'Hyperprolactinemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ovarian disorders </strong>–<strong> </strong>Ovarian disorders that may result in secondary amenorrhea include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>PCOS </strong>–<strong> </strong>PCOS, one of the most common endocrine disorders in females. PCOS is not simply an ovarian disorder; its pathogenesis is complex. The principal features of PCOS include ovulatory dysfunction, androgen excess, polycystic ovaries on ultrasound, and metabolic issues, including obesity. Females with PCOS may present with amenorrhea, but they more commonly have irregular menses (oligomenorrhea). (See <a class="local">'Polycystic ovary syndrome'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>POI </strong>–<strong> </strong>POI refers to menopause prior to age 40 years. It may be due to complete or partial loss of an X chromosome (Turner syndrome), the fragile X premutation, autoimmune ovarian destruction, or, most commonly, unknown causes. (See <a class="local">'Primary ovarian insufficiency (premature ovarian failure)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uterine disorders </strong>–<strong> </strong>Intrauterine adhesions (Asherman syndrome) are the only uterine cause of secondary amenorrhea. This syndrome results from acquired scarring of the endometrial lining, usually secondary to postpartum hemorrhage or endometrial infection followed by instrumentation such as a dilatation and curettage. (See <a class="local">'Uterine disorders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence. Horm Res Paediatr 2017; 88:371.</a></li><li><a class="nounderline abstract_t">Reindollar RH, Novak M, Tho SP, McDonough PG. Adult-onset amenorrhea: a study of 262 patients. Am J Obstet Gynecol 1986; 155:531.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Current evaluation of amenorrhea. Fertil Steril 2006; 86:S148.</a></li><li><a class="nounderline abstract_t">Laufer MR, Floor AE, Parsons KE, et al. Hormone testing in women with adult-onset amenorrhea. Gynecol Obstet Invest 1995; 40:200.</a></li><li><a class="nounderline abstract_t">Rosenfield RL. Clinical review: Adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 2013; 98:3572.</a></li><li><a class="nounderline abstract_t">de Roux N, Young J, Misrahi M, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337:1597.</a></li><li><a class="nounderline abstract_t">Fourman LT, Fazeli PK. Neuroendocrine causes of amenorrhea--an update. J Clin Endocrinol Metab 2015; 100:812.</a></li><li><a class="nounderline abstract_t">Santoro N, Filicori M, Crowley WF Jr. Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone. Endocr Rev 1986; 7:11.</a></li><li><a class="nounderline abstract_t">Gordon CM. Clinical practice. Functional hypothalamic amenorrhea. N Engl J Med 2010; 363:365.</a></li><li><a class="nounderline abstract_t">Perkins RB, Hall JE, Martin KA. Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. J Clin Endocrinol Metab 1999; 84:1905.</a></li><li><a class="nounderline abstract_t">Gaete X, Vivanco M, Eyzaguirre FC, et al. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil Steril 2010; 94:1822.</a></li><li><a class="nounderline abstract_t">Codner E, Merino PM, Tena-Sempere M. Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update 2012; 18:568.</a></li><li><a class="nounderline abstract_t">Molteni N, Bardella MT, Bianchi PA. Obstetric and gynecological problems in women with untreated celiac sprue. J Clin Gastroenterol 1990; 12:37.</a></li><li><a class="nounderline abstract_t">Kakuno Y, Amino N, Kanoh M, et al. Menstrual disturbances in various thyroid diseases. Endocr J 2010; 57:1017.</a></li><li><a class="nounderline abstract_t">Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf) 1999; 50:655.</a></li><li><a class="nounderline abstract_t">Groff TR, Shulkin BL, Utiger RD, Talbert LM. Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism. Obstet Gynecol 1984; 63:86S.</a></li><li><a class="nounderline abstract_t">Grubb MR, Chakeres D, Malarkey WB. Patients with primary hypothyroidism presenting as prolactinomas. Am J Med 1987; 83:765.</a></li><li><a class="nounderline abstract_t">Burgers JA, Fong SL, Louwers YV, et al. Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference? J Clin Endocrinol Metab 2010; 95:E485.</a></li><li><a class="nounderline abstract_t">Grynberg M, Fanchin R, Dubost G, et al. Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population. Reprod Biomed Online 2010; 20:553.</a></li><li><a class="nounderline abstract_t">van Liempt SW, van Rheenen-Flach LE, van Waesberghe JH, et al. Solely inhibin B producing ovarian tumour as a cause of secondary amenorrhoea with hot flushes: case report and review of literature. Hum Reprod 2012; 27:1144.</a></li></ol></div><div id="topicVersionRevision">Topic 104135 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29156452" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3529965" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Adult-onset amenorrhea: a study of 262 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17055812" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Current evaluation of amenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8529955" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hormone testing in women with adult-onset amenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23913942" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical review: Adolescent anovulation: maturational mechanisms and implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371856" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581597" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Neuroendocrine causes of amenorrhea--an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082615" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hypogonadotropic disorders in men and women: diagnosis and therapy with pulsatile gonadotropin-releasing hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660404" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical practice. Functional hypothalamic amenorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10372685" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19796762" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22709979" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Female reproduction and type 1 diabetes: from mechanisms to clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2303686" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Obstetric and gynecological problems in women with untreated celiac sprue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938101" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Menstrual disturbances in various thyroid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468932" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Disturbances of menstruation in hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6700889" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Amenorrhea-galactorrhea, hyperprolactinemia, and suprasellar pituitary enlargement as presenting features of primary hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3674063" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Patients with primary hypothyroidism presenting as prolactinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20843954" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oligoovulatory and anovulatory cycles in women with polycystic ovary syndrome (PCOS): what's the difference?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20122869" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Histology of genital tract and breast tissue after long-term testosterone administration in a female-to-male transsexual population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258664" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Solely inhibin B producing ovarian tumour as a cause of secondary amenorrhoea with hot flushes: case report and review of literature.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
